Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants

Odontology

Volumn 103, Issue 3, 2015, Pages 258-263

  Sivolella, Stefano ^a   De Biagi, Marleen ^a   Brunello, Giulia ^a   Berengo, Mario ^a   Pengo, Vittorio ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Apixaban; Dabigatran; Oral anticoagulants; Oral surgery; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; WARFARIN;

CHEMICALLY INDUCED; DENTAL PROCEDURE; HUMAN; ORAL DRUG ADMINISTRATION; ORAL HEMORRHAGE; ORAL SURGERY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; DABIGATRAN; DENTAL CARE FOR CHRONICALLY ILL; FACTOR XA INHIBITORS; HUMANS; ORAL HEMORRHAGE; ORAL SURGICAL PROCEDURES; PYRAZOLES; PYRIDONES; RIVAROXABAN; WARFARIN;

EID: 84941994191     PISSN: 16181247     EISSN: 16181255     Source Type: Journal    
DOI: 10.1007/s10266-015-0195-4     Document Type: Article

References (38)

1. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:431–41.
2. Little JW. New oral anticoagulants: will they replace warfarin? Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:575–80.
3. Nagarakanti R, Ellis CR. Dabigatran in clinical practice. Clin Ther. 2012;34:2051–60.
4. Jaffer AK. Anticoagulation management strategies for patients on warfarin who need surgery. Cleve Clin J Med. 2006;73(Suppl 1):S100–5.
5. Michota F. Transitions of care in anticoagulated patients. J Multidiscip Healthc. 2013;6:215–28.
6. Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013;52:69–82.
7. Pengo V. Laboratory tests during direct oral anticoagulant treatment? Yes. Intern Emerg Med. 2013;8:371–2.
8. Weitz JI, Gross PL. New oral anticoagulants: which one should my patient use? Hematol Am Soc Hematol Educ Progr. 2012;2012:536–40.
9. Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Härtter S, Harper R, Kappetein AP, Lehr T, Mack MJ, Noack H, Eikelboom JW. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163(931–7):e1.
10. Davis C, Robertson C, Shivakumar S, Lee M. Implications of dabigatran, a direct thrombin inhibitor, for oral surgery practice. J Can Dent Assoc. 2013;79:d74.
11. Aditya S. Oral and parenteral anticoagulants: new kids on the block. J Postgrad Med. 2012;58:275–85.
12. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.
13. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–62.
14. Xarelto®: European medicines agency—EPAR—product information, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed 15 Aug 2013 (first published December 1, 2009). Accessed Sept 2014.
15. Xarelto®: European medicines agency—assessment report, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000944/WC500144718.pdf. Accessed Sept 2014.
16. Eliquis®: European medicines agency—EPAR—product information, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed Sept 2014.
17. Eliquis®: European medicines agency—summary of opinion (post authorisation), 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002148/WC500132869.pdf. Accessed Sept 2014.
18. Eliquis®: FDA accepts for review ELIQUIS® (apixaban) supplemental new drug application for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE, 2013. http://news.bms.com/press-release/fda-accepts-review-eliquis-apixaban-supplemental-new-drug-application-treatment-deep-v. Accessed Sept 2014.
19. Pollack CV Jr. Managing bleeding in anticoagulated patients in the emergency care setting. J Emerg Med. 2013;45:467–77.
20. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–51.
21. van Diermen DE, van der Waal I, Hoogstraten J. Management recommendations for invasive dental treatment in patients using oral antithrombotic medication, including novel oral anticoagulants. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:709–16.
22. Richards D. Guidelines for the management of patients who are taking oral anticoagulants and who require dental surgery. Evid Based Dent. 2008;9:5–6.
23. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. American college of chest physicians. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e326S–50S.
24. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120:2954–62.
25. Baglin TP, Cousins D, Keeling DM, Perry DJ, Watson HG. Safety indicators for inpatient and outpatient oral anticoagulant care: recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol. 2007;136:26–9.
26. Feldens CA, Vitolo MR, Drachler ML. Guidelines for the management of patients who are taking oral anticoagulants and who require dental surgery. Community Dent Oral Epidemiol. 2007;35:215–23.
27. Mingarro-de-León A, Chaveli-López B, Gavaldá-Esteve C. Dental management of patients receiving anticoagulant and/or antiplatelet treatment. J Clin Exp Dent. 2014;6:e155–61.
28. Gómez-Moreno G, Aguilar-Salvatierra A, Martín-Piedra MA, Guardia J, Calvo-Guirado JL, Cabrera M, López-Gallardo C, Castillo T. Dabigatran and rivaroxaban, new oral anticoagulants. New approaches in dentistry. J Clin Exp Dent. 2010;2:e14–8.
29. Palareti G, Ageno W, Ferrari A, Filippi A, Imberti D, Pengo V, Rubboli A, Toni D. Clinical management of rivaroxaban-treated patients. Expert Opin Pharmacother. 2013;14:655–67.
30. Fakhri HR, Janket SJ, Jackson EA, Baird AE, Dinnocenzo R, Meurman JH. Tutorial in oral antithrombotic therapy: biology and dental implications. Med Oral Patol Oral Cir Bucal. 2013;18:e461–72.
31. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M, RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation. 2012;126:343–8.
32. Breik O, Cheng A, Sambrook PJ, Goss AN. Protocol in managing oral surgical patients taking dabigatran. Aust Dent J. 2014;59:296–301.
33. Romond KK, Miller CS, Henry RG. Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:e191–5.
34. Turpie AG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108:876–86.
35. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012;126:2428–32.
36. Fellows SE, Rosini JM, Curtis JA, Volz EG. Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency. J Emerg Med. 2013;44:e221–5.
37. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46:e10.
38. Harel Z, Sholzberg M, Shah PS, Pavenski K, Harel S, Wald R, Bell CM, Perl J. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol. 2014;25:431–42.